Robert S Woodward

Dr. Robert S Woodward

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RWRobert S Woodward
Robert S Woodward
MSMark A. Schnitzler
Mark A. Schnitzler
JBJack Baty
Jack Baty
JLJeffrey A. Lowell
Jeffrey A. Lowell
LLLissa Lopez-Rocafort
Lissa Lopez-Rocafort
DBDaniel C. Brennane
Daniel C. Brennane
This study sought to determine 1) the incidence and costs of new onset diabetes mellitus (NODM) associated with maintenance immunosuppression regimens following renal transplantation and 2) whether ...

1 January 2006 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AKA. Kutinova
A. Kutinova
RWRobert S Woodward
Robert S Woodward
JRJ.F. Ricci
J.F. Ricci
DBD.C. Brennan
D.C. Brennan
We compared the graft survival and accumulative costs associated with sepsis and pneumonia pre- and post-transplantation. We analyzed 44 916 first kidney transplants from 1995 to 2001 USRDS where Medicare was the primary payer. We drew five cohorts for each disease from the baseline population: patients who had a disease onset in the first or second years pre-transplantation (cohorts 1 and 2) or post-transplantation (cohorts 3 and 4) and patients who were disease-free (cohort 5). For each cohort, we calculated graft survival and average accumulated Medicare payments (AAMPs) for the two pre- and post-transplantation years. Graft survival: new-onset sepsis and pneumonia both significantly (p <0.01) lowered graft survival during the year of onset. AAMPs: the AAMPs incurred by sepsis- (pneumonia-) free patients during the first and second years post-transplantation were dollar 50,000 and 13,000 (dollar 51,100 and 13,500), respectively. Patients with a sepsis (pneumonia) onset post-transplantation cost on average dollar 48,400 (dollar 38,400) extra (p<0.01). Episodes of sepsis and pneumonia have a strong and independent impact on graft survival and costs.

11 November 2008 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RWRobert S Woodward
Robert S Woodward
TPT. F. Page
T. F. Page
RSR. Soares
R. Soares
MSM. A. Schnitzler
M. A. Schnitzler
KLK. L. Lentine
K. L. Lentine
DBD. C. Brennan
D. C. Brennan
Beginning January 1, 2000, Medicare extended coverage of immunosuppression medications from 3 years to lifetime based on age >65 years or disability. Using United States Renal Data System (USRDS) data for Medicare‐insured recipients of kidney transplants between July 1995 and December 2000, we identified four cohorts of Medicare‐insured kidney transplant recipients. Patients in cohort 1 were individuals who were both eligible and received lifetime coverage. Patients in cohort 2 would have been eligible, but their 3‐year coverage expired before lifetime coverage was available. Patients in cohort 3 were ineligible for lifetime coverage because of youth or lack of disability. Patients in cohort 4 were transplanted between 1995 and 1996 and were ineligible for lifetime coverage. Incomes were categorized by ZIP code median household income from census data. Lifetime extension of Medicare immunosuppression was associated with improved allograft survival among low‐income transplant recipients in the sense that the previously existing income‐related disparities in graft survival in cohort 2 were not apparent in cohort 1. Ineligible individuals served as a control group; the income‐related disparities in graft survival observed in the early cohort 4 persisted in more recent cohort 3. Multivariate proportional hazards models confirmed these findings. Future work should evaluate the cost effectiveness of these coverage increases, as well as that of benefits extensions to broader patient groups.

15 September 2005 in Transplantation
Verified
Journal Article
Open access
RWRobert S Woodward
Robert S Woodward
AKAndrea Kutinova
Andrea Kutinova
MSMark A. Schnitzler
Mark A. Schnitzler
DBDaniel Brennan
Daniel Brennan
Tacrolimus is associated with fewer acute rejections than cyclosporine, but a greater risk of new onset diabetes mellitus. When compared to no tacrolimus among nondiabetics in a large patient registry, it is associated with improved graft survival. The current study used the same patient registry to compare more correctly graft survival between nondiabetic renal transplant recipients initially immunosuppressed with either of the two most frequently used calcineurin inhibitors, tacrolimus or modified cyclosporine (CsA). We examined data provided by the United States Renal Data System (USRDS) on all first, single-organ, renal transplants to nondiabetic recipients that occurred during the years 1996 to 2000. Importantly, we then limited the study to patients on CsA (n=7,867) or tacrolimus (n=3,082) as the initial agent. Patients with both or neither were excluded. We used Cox proportional hazards regressions to estimate the tacrolimus-related relative risk of graft failure, controlling for other significant donor, recipient, and transplant characteristics We found that tacrolimus patients had graft failure rates equivalent to those of CsA patients (hazard ratio= 1.031, P=0.631) Although tacrolimus is being used with increasing frequency, analyses of the USRDS data show no net advantage in the ultimate transplantation outcome, graft survival. Given the higher acquisition price of tacrolimus compared to CsA and the similar risk of graft failure, further studies should be conducted to define those patient groups for which tacrolimus might be cost-effective.

1 June 2011 in Value in Health
Verified
Journal Article
Closed access
RWRobert S Woodward
Robert S Woodward
MFMarc C. Flore
Marc C. Flore
GMGerardo Machnicki
Gerardo Machnicki
DBDaniel C. Brennan
Daniel C. Brennan

14 July 2011 in Health Economics
Verified
Journal Article
Closed access
PDF file
RWRobert S Woodward
Robert S Woodward
LWLe Wang
Le Wang